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Abstract
Background: Women with PCOS have been reported to be at increased risk of a number of
gynaecological neoplasias, including endometrial, breast, and ovarian cancer. Studies of the possible
association of genetic variation in progesterone receptor polymorphism with risk of ovarian and
breast cancer have concentrated on a variant known as PROGINS.
Methods: Ninety-five young women with PCOS and 99 healthy control women were included in
our study. All subjects underwent venous blood drawing for complete hormonal assays, lipid
profile, glucose, insulin and PROGINS polymorphism genetic study.
Results: In PROGINS polymorphism results; in both control and the patient groups T1/T1 has
been detected in high levels. But for genotype (p = 0.178) and allele (p = 0.555) frequencies both
of the groups give similar results. Statistically significant difference has been detected on serum FSH
levels for T1/T1 genotype according to T2/T2 genotype.
Conclusion:  No relation has been detected between the inflammatory and oxidative stress
factors, and PROGINS polymorphism alleles. This may be because the PCOS patients are young
and their BMI means are normal and their CIMT and oxidative stress markers are like healthy
women.
Background
Polycystic ovary syndrome (PCOS) is one of the most
encountered endocrine malfunctions, which typically
occur with chronic anovulation and hyperandrogenism
[1]. Almost 15% of the women at reproductive period
complain about PCOS [2]. Women with PCOS have been
reported to be at increased risk of a number of gynaeco-
logical neoplasias, including endometrial, breast, and
ovarian cancer [3]. The reproductive abnormalities in
PCOS include chronic anovulation, prolonged exposure
to oestrogen, progesterone deficiency, and androgen
excess, which may contribute to an increased risk for
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gynaecological cancers in which the hormonal milieu is
an important contributor to aetiology and prognosis.
Oxidative damage has been implicated in the pathogene-
sis of many chronic progressive diseases, such as cancer,
inflammation, and neurodegenerative disorders. Emerg-
ing risk factors such as oxidative stress, inflammation and
endothelial cell activation are thought to play integral
roles in the development of atherosclerotic lesions and
cancer [4,5].
In women with PCOS who are anovulatory or oligo-ovu-
latory, the regulatory roles of progesterone and progester-
one withdrawal in the endometrial tissue are suboptimal
or absent. In previously studies, heterozygous PROGINS
constitution might lead to an over expression of proges-
terone inducible target genes even at physiologic levels of
progesterone [6]. Moreover, this mechanism may contrib-
ute to the process of malignant transformation, athero-
sclerosis, Oxidative stress, insulin resistance.
The human progesterone receptor is a single copy gene
located on chromosome 11q22-23 [7]. The actions of pro-
gesterone are mediated by two functionally distinct recep-
tor isoforms, PR-A and PR-B, which are expressed from a
single gene as a result of transcription from two alternative
promoters [8]. Progesterone acts as a mitogen for breast
tissue [9,10], and adding progestin's to menopausal oes-
trogen therapy increases mammographyical density,
which is in turn associated with breast cancer risk [10].
Studies of the possible association of genetic variation in
PGR with risk of ovarian [11-13] and breast cancer [14]
have concentrated on a variant known as PROGINS. Pro-
gesterone is involved in the regulation of VSMC prolifera-
tion and modulates the synthesis of proinflammatory
proteins such as monocyte chemoattractant protein-1,
matrix metalloproteinase, E-selectin, and intercellular
adhesion molecule-1 [15,16].
It is not known what impact PROGINS polymorphism
may have on the inflammation process of the vasculature.
The purpose of present study is to investigate the insulin
resistance, inflammatory markers (hs-CRP, fibrinogen)
and PROGINS Polymorphisms in young women with
PCOS.
Methods
Informed consent had been obtained before study in all
patients and controls. Ninety-five young women (mean
age, 24.27 ± 5.44 SD years) with PCOS and 99 healthy
control women (mean age, 26.41 ± 5.65 SD years) were
included in our study. PCOS was defined by the Rotter-
dam PCOS consensus criteria [17]. In all subjects
(patients and controls) baseline plasma concentrations of
LH, FSH, total testosterone, 17-hydroxyprogesterone (17-
OHP), dihydroepiandrosterone sulphate (DHEA-S),
oestradiol, SHBG and prolactin (PRL) were determined
during the follicular phase (cycle days 5–7) after sponta-
neous or progestin-induced cycles.
Patients who had DM, hyperprolactinemia, congenital
adrenal hyperplasia (diagnosed with the adrenocortico-
tropic hormone stimulation test), thyroid disorders,
Cushing's syndrome, hypertension, hepatic or renal dys-
function were excluded from the study. Confounding
medications, including oral contraceptive agents, hyper-
tensive medications and insulin sensitizing drugs, and
those, which may affect the metabolic criteria, were ques-
tioned.
Initially, ninety-nine patients were taken to the study but
4 patients were left voluntarily due to different personal
reasons (genotype success rate = 96,6%). Similarly, 5 indi-
vidual of 103 individuals were left the study voluntarily
(genotype success rate = 95,8%). In all subjects, a clinical
examination and an evaluation of hirsutism score by the
Ferriman-Gallwey Classification were performed for each
woman, a BMI (determined as weight in kg/height in m)
were evaluated [18]. Individuals participating in the con-
trol group were the individuals who had laboratorial nor-
mal f-testosterone, total – testosterone, FSH, LH and basal
insulin without acne, alopecia, menstrual disorder, and
hirsutism. Healthy young volunteer females matched for
age, body mass index (BMI), and allele frequency, were
included and considered as the control group. Their
healthy state was determined by medical history, physical
and pelvic examination, and complete blood chemistry.
Study protocol
At study entry, all subjects underwent venous blood draw-
ing for complete hormonal assays, lipid profile, glucose,
and insulin and PROGINS polymorphism genetic study.
All blood samples were obtained in the morning between
08.00 and 09.00 hours after an overnight fasting, and rest-
ing in bed during early follicular phase of the spontaneous
or P-induced menstrual cycle. During the same visit, all
subjects underwent anthropometric measurements
including BMI and detail history, systolic and diastolic
blood pressure and Doppler ultrasonographic (US) exam-
ination for the evaluation of CIMT. In present study, data
regarding the metabolic alteration, oxidative stress mark-
ers and CIMT outcomes, and the genetic evaluation of
PROGINS polymorphism will be shown and discussed.
Biochemical and hormonal assay
Serum concentrations of hs-CRP were determined by an
immunonephelometric assay (N-high-sensitivity CRP;
Dade Behring); intra and interassay CV were 1.72 and
2.80%, respectively. Serum total cholesterol, LDL and
HDL cholesterol, aspartate aminotransferase (AST),Cardiovascular Diabetology 2007, 6:29 http://www.cardiab.com/content/6/1/29
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alanine aminotransferase (ALT), and γ-glutamyltrans-
ferase (GGT) were measured by Olympus AU 2700 auto-
mated analyzer. Plasma insulin concentrations were
determined by Immunolite 2000 using two-site chemilu-
minescent immunometric assay. Serum glucose levels
were determined by the glucose oxidase method. Plasma
LH, FSH, PRL, oestradiol, progesterone, 17-OHP, testo-
sterone, and dehydroepiandrosterone sulphate were
measured by RIA. Insulin resistance was calculated using
the homeostasis model assessment insulin resistance
index (HOMA-IR) [19], according to the following for-
mula:
Genetic study
PROGINS polymorphism was studied in 95 (genotype suc-
cess rate 96%) young women with PCOS and 99 healthy
women (genotype success rate 94%) control group.
PROGINS genotyping
i-DNA purification
Genomic DNA from patients and healthy controls was
extracted from peripheral blood leukocytes using with
QIAmp DNA Blood Mini Kits 50 (Qiagen GmbH, Hilden,
Germany) according to the manufacturer's instructions.
For the PROGINS polymorphism, the following oligonu-
cleotide primers (TIB MOLBIOL Syntheselabor, Berlin-
Germany), were used:
Forward 5'TAT GAG CTA TTT GAG TAA AGC CT-3'
Reverse – 5'-TTC TTG CTA AAT GTC TGT TTT AA-3'
ii-PCR conditions
Amplification was carried out on a GeneAmp PCR System
9700(PE Applied Biosystems, Foster City, CA) in a 25 μl
reaction mixture in 0.2 ml thin-wall PCR strip tubes (Axy-
gen Scientific, Inc., CA) containing 1 μl genomic DNA
solution, GeneAmp Gold Buffer(15 mmol/l Tris-HCl, pH
8.0, 50 mmol/l KCl; PE Applied Biosystems), 1.5 mmol
MgCl2, 50 μmol/l each of the dGTP, dATp, dTTP and
dCTP (Promega, Madison, WI),5 pmol each forward and
reverse primers and 1.0 U AmpliTaq Gold polymerase(PE
Applied Biosystems). The cycling conditions comprised a
hot start at 95°C for 10 min, followed by 35 amplification
cycles at 95°C for 30 s, 55°C for 60 s, and 72°C for 45 s,
followed by one elongation step at 72°C for 5 min. The
PCR products were applied to electrophoretic analysis
with the use of a 2% agarose gel Two DNA fragments
could be detected: a 185 bp DNA fragment representing
'T1'allele (wild-type) and a 485 bp DNA fragment repre-
senting 'T2' allele.
Methods for plasma MDA, NO, total sulfhydryl group 
measurements
All reagents were purchased from Sigma and Merck. MDA
was determined by a modified spectrophometric method
of Yagi K [20] using tetrametoxypropan as Standard and
BioTek MicroQuant microplate reader. NO was deter-
mined by measuring stable NO end-products-nitrite and
nitrate levels using Miranda' s spectrophometric method
[21] while total sulfhydryl groups was measured using Ell-
man's reagent by Sedlak and Lindsay's method [22].
Radiological measurement
All examinations were performed by one of the two radi-
ologists experienced in US examinations using an equip-
ment of Sonoline Elegra system (Siemens, Erlangen,
Germany) with a 7.5 MHz linear-array transducer. The
CIMT measurements were performed on the mid portion
of the common carotid artery for intima thickness and
total thickness including intima and media measurement.
Statistical analysis
SPSS 14.0 for windows (SPSS Inc. Chicago USA) was used
for statistical analysis of the results. P < 0.05 values were
accepted as statistically significant. The characteristics of
the patients with PCOS and the mean plasma glucose, and
insulin, dehydroepiandrosterone sulphate, 17β-estradiol,
homocysteine, 17-hydroxyprogesterone, prolactin, testo-
sterone levels between the two clinical groups were com-
pared by Student's t test for unpaired data and between
and within the different groups (T1/T1, T1/T2, T2/T2) of
PROGINS polymorphism with the ANOVA.
Univariate logistic regression analysis was performed in
order to show which one of the parameters for which sta-
tistically significantly difference was found at Student's t
test between patient and control groups was more associ-
ated with PCOS. Allelic and genotypic frequencies were
determined from observed genotype counts, and the
expectations of the Hardy-Weinberg equilibrium were
evaluated by χ2 analysis. Differences in the genotype dis-
tribution between different groups were assessed by Pear-
son's χ2 test of heterogeneity. All results were expressed as
means ± SD.
Results
Ninety-five PCOS patients and 99 Healthy controls partic-
ipated in this study. PCOS patients were divided into
three sub-groups (T1/T1, T1/T2, T2/T2) according to their
PROGINS gene polymorphism. The result of the bio-
chemical, hormonal and oxidative stress parameters and
the Carotid intimae media thickness of the PCOS patients
sub-groups according to their PROGINS polymorphism is
HOMA IR
fasting serum insulin  mU/ml
fasting plasma gluco −=
× ()
s se mmol/l ()
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shown in Table 1. In the patients group no statistically sig-
nificant differences in HDL – cholesterol, LDL – choles-
terol, total cholesterol, triglyceride, fasting blood glucose,
fasting serum insulin, HOMA-IR, prolactine, f-testoster-
one, total testosterone, estradiol, DHEAS, fibrinogen, hs-
CRP and oxidative stress parameters have been detected
(Table 1) (p > 0.05. But a statistically significant difference
has been detected on serum FSH levels for T1/T1 genotype
according to T2/T2 genotype. In PROGINS polymor-
phism results; in both control and the patient groups T1/
T1 has been detected in high levels (Figure 1). But for gen-
otype (p = 0.178) and allele (p = 0.555) frequencies both
of the groups give similar results (Table 2).
Discussion
The importance of this study is working on progesterone
receptor polymorphism and searching the effects of this
polymorphism on the Oxidative stress markers, inflam-
matory markers and CIMT of the PCOS patients for whom
the gynaecological malignancies show increases. Proges-
terone and estrogen are the main steroid hormones
involved in normal reproduction functions. An abnor-
mality may also occur in PGR receptor except for the pro-
gesterone itself. Several polymorphisms have been
identified in PGR; they include S344T, G393G, V660L,
H770H, and the PROGINS allele [23,24]. The physiologi-
cal effects of progesterone are completely dependent on
the presence of the human PGR, a member of the steroid-
receptor superfamily of nuclear receptors [25]. As a conse-
quence of this receptor, PROGINS encodes for a receptor
protein with increased stability and increased hormone-
induced transcriptional activity [26]. Functional polymor-
phisms in genes involved in proliferation and cellular
homeostasis may affect the risk for benign and malignant
disorders.
Inflammation and progesterone receptor polymorphism 
(PROGINS)
Chronic inflammation has been associated with a risk of
atherosclerosis and cancer development. In previously
studies have reported an endothelial dysfunction in
women with PCOS [27,28]. Accumulating evidence also
suggests that atherosclerosis represents a chronic inflam-
matory process and inflammatory markers like CRP and
fibrinogen, homocysteine provide an adjunctive method
for global assessment of cardiovascular risk [29,30].
Recent data also suggest that hs-CRP may directly pro-
mote endothelial dysfunction by increasing the synthesis
of soluble adhesion molecules, increasing monocyte che-
moattractant protein secretion [31,32]. As a result of this
study; no difference has been detected on different geno-
types of functional progesterone receptor polymorphism
(PROGINS) according to hs-CRP and fibrinogen proin-
flammatory markers, which are important factors for early
atherosclerosis in PCOS.
Insulin resistance and progesterone receptor 
polymorphism (PROGINS)
The link of PCOS with insulin resistance was subse-
quently established by clinical studies characterizing the
profound insulin resistance in obese and lean PCOS
patients. Insulin resistance, hyperinsulinemia, and beta
cell dysfunction are very common in PCOS, but are not
required for the diagnosis [33].
In PCOS, stimulation of reactive oxygen species (ROS)
generation from mononuclear cells (MNCs) by hypergly-
caemia may play a role in inflammation through the
release of TNFα from circulating MNCs. The oxidative
effects of insulin have been demonstrated in vitro and in
response to both physiological and pharmacological insu-
lin infusions in vivo [34,35]. The estradiol hormone level
is high in a menstrual cycle, free radicals produced as a
consequence of exercise may be easily removed by inac-
tive women with regular menstrual cycles [36]. In this
study no statistically significant difference has been
detected according to plasma glucose, estradiol level,
insulin levels and HOMA-IR between the PCOS patients
with different functional progesterone receptor polymor-
phism (PROGINS).
Oxidative stress parameters and progesterone receptor 
polymorphism (PROGINS)
In previously study, did not show a significant correlation
between progesterone receptor polymorphism and oxida-
tive system markers in PCOS. It has been reported from
experiments in rats that progesterone may also have anti-
oxidant properties in some circumstances [37]. However,
these observations have not been reported in humans.
MDA, NO, SH Levels and HOMA-IR Index with PCOS  according to The PROGINS genotypes Figure 1
MDA, NO, SH Levels and HOMA-IR Index with PCOS 
according to The PROGINS genotypes.Cardiovascular Diabetology 2007, 6:29 http://www.cardiab.com/content/6/1/29
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In our study, the Oxidative stress markers have been eval-
uated in the PCOS patients with progesterone receptor
polymorphism (PROGINS). In the presence of inflamma-
tion MDA and -SH groups increase but "NO" levels
decreases in tissues and blood [38]. Under normal physi-
ological conditions, cellular ROS generation is counter-
balanced by the action of antioxidant enzymes and other
redox molecules. The balance between   generation
and elimination is important for maintaining proper cel-
lular redox states. A moderate increase in ROS can stimu-
late cell growth and proliferation [39]. However, excessive
ROS accumulation will lead to cellular injury, such as
damage to DNA [40], protein, and lipid membrane
[41,42]. Because of their potential harmful effects, exces-
sive ROS must be promptly eliminated from the cells by a
variety of antioxidant defence mechanisms, including
important enzymes, such as superoxide dismutase (SOD),
catalase, and various peroxidases. Compelling evidence
suggests that cancer cells are generally under ROS stress
[43]. Although the precise mechanisms responsible for
increased ROS stress in cancer cells have not be defined,
the increase in ROS generation is attributed to active cel-
lular metabolic activity under the influence of oncogenic
signals and/or to mitochondrial malfunction in cancer
cells [44].
In our study no statistically significant difference has been
detected according to NO, MDA and -SH levels in the
patient groups with different PROGINS genotype. It is
known that cancer risk (breast, endometrial) in PCOS
patients is higher than the healthy women. Our patients
are young and the period that they encountered negative
metabolic differences is shorter. Differences on metabolic
parameters CIMT and oxidative stress markers for these
genotypes may occur after a time period.
In previous studies coronary calcification, as a risk factor
of CVD was found to be significantly increased in patients
with PCOS in comparison with healthy controls [45,46].
In our study no statistically significant difference has been
detected according to f-testosteron, total testosteron and
estrogen levels in the patient groups with different PRO-
GINS genotype.
As a result no relation has been detected between the
inflammatory and oxidative stress factors, and PROGINS
polymorphism alells. This may be because the patients are
young and their BMI means are normal and their CIMT
and oxidative stress markers are like healthy women. In
the future we planned to study on older PCOS patients
and evaluate these parameters for this group.
O2
−
Table 1: Metabolic and Hormonal Parameters with PCOS According to the PROGINS Genotypes.
PCOS Patients (mean ± SD deviation)
T1/T1 T1/T2 T2/T2 P
Insulin levels (mIU/ml) 15.3 ± 36.11 15.7 ± 19.01 6.67 ± 4.04 0,39
Fasting blood glucose (mg/dL) 90.8 ± 7.7 91.95 ± 11.8 96.67 ± 10 0,55
s-CRP (mg/dl) 0.33 ± 0.3 0.657 ± 1.48 0.15 ± 0.05 0,39
Fibrinogen (mg/dl) 357.2 ± 88.6 384.2 ± 133 338.6 ± 30.4 0,95
Right CIMT (milimeter) 0.42 ± 0.51 0.424 ± 0.43 0.43 ± 0.05 0,85
Left CIMT (milimeter) 0.429 ± 0.52 0.424 ± 0.62 0.433 ± 0.57 0,85
17-OHP (ng/ml) 5.3 ± 2.8 1.9 ± 0.92 2.2 ± 0.8 0,46
HDL – Cholesterol (mg/dL) 56.58 ± 15.3 57.65 ± 14.2 63.6 ± 24.77 0,45
LDL – Cholesterol (mg/dL) 117.1 ± 33.1 109.6 ± 27.5 129.0 ± 47.6 0,42
Triglycerid (mgl/dL) 110.8 ± 60.1 143.7 ± 88.1 89.3 ± 28.5 0,42
Cholesterol (mg/dL) 197.1 ± 44.2 194.0 ± 37.3 210.3 ± 61.7 0,84
F-testosterone (nmol/Ll) 2.91 ± 1.6 4.16 ± 2.8 2.5 ± 0.7 0,12
FSH (mIU/ml) 5.72 ± 2.16 4.9 ± 1.75 3.23 ± 1.86 0,04
If P < 0.05 in chi-square test it is accepted as statistically significant.
Table 2: Genotype and Allele Frequencies of the PRP PROGINS 
Polymorphism in Women With PCOS And Healthy Controls
PRPs PCOS Patients 
(n = 95)
Control Groups 
(n = 99)
Genotypes
T1/T1 71 (74.7%) 67 (67.7%)
T1/T2 21 (22.1%) 28 (28.3%)
T2/T2 3 (3.2%) 4 (3.6%)
T1/T2 + T2/T2 24 (25.3%) 32 (31.9%)
Alleles
T1 163 (85.8%) 162 (81.8%)
T2 27 (14.2%) 36 (18.2%)
n, number of patients who could be genotyped successfully.Cardiovascular Diabetology 2007, 6:29 http://www.cardiab.com/content/6/1/29
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Abbreviations
PCOS – polycystic ovary syndrome, BMI – body mass
index, CI – confidence interval, CV – coefficient(s) of var-
iation, MLRA-Multipl Logistic Regression Analysis, CVD-
cardiovascular disease, DHEAS – dehydroepiandroster-
one sulphate, E2-17β-estradiol, Hcy-homocysteine, 17-
OHP-17-hydroxyprogesterone, P – progesterone, PRL –
prolactin, T-testosterone, CIMT-Carotid intima-media
thickness, BMI-body mass index, FSH-follicle stimulating
hormone, LH-luteinising hormone, HOMA-IR – homeos-
tasis model of assessment insulin resistance.
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